Maze Therapeutics, Inc.
1.7M
$1.50B
-13.58
$-3.05
No price alerts set. Add an alert to get notified!
-13.58
5.02
$-3.05
-36.94%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ARDX
Ardelyx, Inc.
|
$5.48 | -3.69% | -21.67 | $1.34B | 1.27 |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$9.33 | -2.41% | 7.46 | $1.96B | -4.01 |
|
IMNM
Immunome, Inc.
|
$19.61 | -3.92% | -8.06 | $1.72B | 0.01 |
|
NTLA
Intellia Therapeutics, Inc.
|
$12.37 | -6.57% | -3.25 | $1.46B | 0.14 |
|
PHVS
Pharvaris N.V.
|
$27.35 | -0.15% | -8.89 | $1.78B | 0.00 |
|
SION
Sionna Therapeutics, Inc.
|
$36.16 | -4.74% | -19.20 | $1.63B | 0.03 |
|
SYRE
Spyre Therapeutics, Inc.
|
$47.31 | -0.44% | -105.48 | $2.86B | 0.00 |
|
TRVI
Trevi Therapeutics, Inc.
|
$11.33 | -3.98% | -38.55 | $1.45B | 0.00 |
|
WVE
Wave Life Sciences Ltd.
|
$6.37 | 2.66% | -5.61 | $1.20B | 0.03 |
|
ZYME
Zymeworks Inc.
|
$24.18 | -2.07% | -22.45 | $1.80B | 0.07 |
* Peer stocks are selected based on market capitalization and sector
$53.65
$6.71
$0.00
0.00%
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
